FDA approves Novavax COVID-19 vaccine
Digest more
While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.
Regulators will soon “unleash a massive framework” for how vaccines are tested and approved, according to FDA Commissioner Marty Makary.
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.”